Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


Articles published in Eur J Radiol

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    June 2025
  1. SINGH D, Chandran A, Panebianco V, Vilaseca J, et al
    MRI capacity assessment for prostate cancer screening in five sites of Europe.
    Eur J Radiol. 2025;190:112235.
    PubMed     Abstract available


    May 2025
  2. SHIN JI, Park KJ, Park MY, Kim MH, et al
    Diagnostic performance of biparametric MRI according to prostate imaging quality (PI-QUAL) version 2: Analysis of Multi-Institutional Data.
    Eur J Radiol. 2025;189:112209.
    PubMed     Abstract available


    March 2025
  3. ZHU W, Tang Y, Qi L, Gao X, et al
    Machine learning models for enhanced diagnosis and risk assessment of prostate cancer with (68)Ga-PSMA-617 PET/CT.
    Eur J Radiol. 2025;186:112063.
    PubMed     Abstract available


  4. NIEUWENHOVE SV, Lhommel R, Pasoglou V, Damme JV, et al
    Fast (< 30 min) "All-in-One" whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to (68)Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT.
    Eur J Radiol. 2025;186:112033.
    PubMed     Abstract available


  5. PAUSCH AM, Elsner C, Rupp NJ, Eberli D, et al
    Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer.
    Eur J Radiol. 2025;186:112028.
    PubMed     Abstract available


    February 2025
  6. TOKUDA B, Yamada K, Kozawa N, Takahata A, et al
    Temporal Evolution of multiparametric magnetic resonance imaging findings following lesion-targeted focal microwave tissue coagulation for localized prostate cancer.
    Eur J Radiol. 2025;185:111995.
    PubMed     Abstract available


  7. PAUSCH AM, Ghafoor S, Notter R, Benke-Bruderer S, et al
    MRI-based risk stratification for clinically significant prostate cancer detection at biopsy: The value of zonal-specific PSA density and PSHS.
    Eur J Radiol. 2025;184:111982.
    PubMed     Abstract available


  8. WALTER-RITTEL TC, Frisch A, Hamm CA, Baumgartner GL, et al
    Automated 24-sector grid-map algorithm for prostate mpMRI improves precision and efficacy of prostate lesion location reporting.
    Eur J Radiol. 2025;183:111897.
    PubMed     Abstract available


    December 2024
  9. PONSIGLIONE A, Stanzione A, Minieri A, Musella R, et al
    Impact of software-assisted structured reporting on radiology residents approaching prostate MRI.
    Eur J Radiol. 2024;183:111889.
    PubMed     Abstract available


  10. ASFUROGLU U, Asfuroglu BB, Ozer H, Inan MA, et al
    A comparative analysis of techniques for measuring tumor contact length in predicting extraprostatic extension.
    Eur J Radiol. 2024;181:111753.
    PubMed     Abstract available


    October 2024
  11. BAYERL N, Adams LC, Cavallaro A, Bauerle T, et al
    Assessment of a fully-automated diagnostic AI software in prostate MRI: Clinical evaluation and histopathological correlation.
    Eur J Radiol. 2024;181:111790.
    PubMed     Abstract available


  12. KLEIBURG F, de Geus-Oei LF, Luelmo SAC, Spijkerman R, et al
    PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
    Eur J Radiol. 2024;181:111774.
    PubMed     Abstract available


    September 2024
  13. PONSIGLIONE A, Cereser L, Spina E, Mannacio L, et al
    PI-QUAL version 2: A Multi-Reader reproducibility study on multiparametric MRI from a tertiary referral center.
    Eur J Radiol. 2024;181:111716.
    PubMed     Abstract available


    August 2024
  14. YADAV D, Dutruel SP, O'Dwyer E, Ricaurte-Fajardo A, et al
    PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer.
    Eur J Radiol. 2024;180:111711.
    PubMed     Abstract available


  15. BECKER AS, Woo S, Leithner D, Tong A, et al
    The "Hungry Judge" effect on prostate MRI reporting: Chronobiological trends from 35'004 radiologist interpretations.
    Eur J Radiol. 2024;179:111665.
    PubMed     Abstract available


    June 2024
  16. KLUCKERT J, Hotker AM, Da Mutten R, Konukoglu E, et al
    AI-based automated evaluation of image quality and protocol tailoring in patients undergoing MRI for suspected prostate cancer.
    Eur J Radiol. 2024;177:111581.
    PubMed     Abstract available


    April 2024
  17. FRANSEN SJ, Roest C, Van Lohuizen QY, Bosma JS, et al
    Using deep learning to optimize the prostate MRI protocol by assessing the diagnostic efficacy of MRI sequences.
    Eur J Radiol. 2024;175:111470.
    PubMed     Abstract available


  18. PAUSCH AM, Elsner C, Rupp NJ, Eberli D, et al
    MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score.
    Eur J Radiol. 2024;175:111463.
    PubMed     Abstract available


    March 2024
  19. QUENTIN M, Boschheidgen M, Radtke JP, Spohn F, et al
    MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
    Eur J Radiol. 2024;175:111436.
    PubMed     Abstract available


    January 2024
  20. GIGANTI F, Asbach P
    The backbone of prostate MRI: Technical acquisition and image quality.
    Eur J Radiol. 2024;172:111320.
    PubMed    


    December 2023
  21. REN X, Nur Salihin Yusoff M, Hartini Mohd Taib N, Zhang L, et al
    (68)Ga-prostate specific membrane antigen-11 PET/CT versus multiparametric MRI in the detection of primary prostate cancer: A systematic review and head-to-head comparative meta-analysis.
    Eur J Radiol. 2023;170:111274.
    PubMed     Abstract available


  22. HARTH C, De Vulder N, Hermie L, Vanlangenhove P, et al
    Stereotactic transgluteal prostatic biopsy using Cone-Beam CT navigation and prebiopsy MRI image fusion in a patient without rectal access.
    Eur J Radiol. 2023;170:111265.
    PubMed    


  23. KHAN A, Moore CM, Minhaj Siddiqui M
    Prostate MRI and image quality: The urologist's perspective.
    Eur J Radiol. 2023;170:111255.
    PubMed     Abstract available


  24. WENDEROTT K, Krups J, Luetkens JA, Gambashidze N, et al
    Prospective effects of an artificial intelligence-based computer-aided detection system for prostate imaging on routine workflow and radiologists' outcomes.
    Eur J Radiol. 2023;170:111252.
    PubMed     Abstract available


    November 2023
  25. PAUSCH AM, Ghafoor S, Kluckert J, Rupp NJ, et al
    Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters.
    Eur J Radiol. 2023;170:111227.
    PubMed     Abstract available


  26. AGGARWAL P, Singh H, Das CK, Mavuduru RS, et al
    Potential role of (68)Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study.
    Eur J Radiol. 2023;170:111218.
    PubMed     Abstract available


  27. REHMAN I, Pang E, Harris AC, Chang SD, et al
    Bi-parametric prostate MRI with a recall system for contrast enhanced imaging: Improving accessibility while maintaining quality.
    Eur J Radiol. 2023;169:111186.
    PubMed     Abstract available


  28. FLEMING H, Dias AB, Talbot N, Li X, et al
    Inter-reader variability and reproducibility of the PI-QUAL score in a multicentre setting.
    Eur J Radiol. 2023;168:111091.
    PubMed     Abstract available


    October 2023
  29. AL-MONAJJED R, Radtke JP, Thomas M, Boschheidgen M, et al
    Multiparametric MRI characteristics of prostatitis and atrophy in the peripheral zone in men without prostate cancer.
    Eur J Radiol. 2023;169:111151.
    PubMed     Abstract available


  30. ZHANG KS, Mayer P, Glemser PA, Tavakoli AA, et al
    Are T2WI PI-RADS sub-scores of transition zone prostate lesions biased by DWI information? A multi-reader, single-center study.
    Eur J Radiol. 2023;167:111026.
    PubMed     Abstract available


  31. SABBAH M, Gutierrez P, Puech P
    MA-QC: Free online software for prostate MR quality control and PI-QUAL assessment.
    Eur J Radiol. 2023;167:111027.
    PubMed     Abstract available


    September 2023
  32. SINGH S, Giganti F, Dickinson L, Rogers H, et al
    Prostate MR image quality of apparent diffusion coefficient maps versus fractional intracellular volume maps from VERDICT MRI using the PI-QUAL score and a dedicated Likert scale for artefacts.
    Eur J Radiol. 2023;168:111109.
    PubMed     Abstract available


  33. YILMAZ EC, Harmon SA, Belue MJ, Merriman KM, et al
    Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI.
    Eur J Radiol. 2023;168:111095.
    PubMed     Abstract available


    August 2023
  34. THIJSSEN LCP, de Rooij M, Barentsz JO, Huisman HJ, et al
    Radiomics based automated quality assessment for T2W prostate MR images.
    Eur J Radiol. 2023;165:110928.
    PubMed     Abstract available


  35. DEIVASIGAMANI S, Kotamarti S, Adams ES, Seguier D, et al
    Reconciling discordance between PI-RADS 4 lesions and targeted biopsy: Early experience of a multidisciplinary quality improvement protocol with PI-RADS 4 subcategorization.
    Eur J Radiol. 2023;165:110929.
    PubMed     Abstract available


    June 2023
  36. URSPRUNG S, Herrmann J, Joos N, Weiland E, et al
    Accelerated diffusion-weighted imaging of the prostate using deep learning image reconstruction: A retrospective comparison with standard diffusion-weighted imaging.
    Eur J Radiol. 2023;165:110953.
    PubMed     Abstract available


  37. ZHANG KS, Neelsen CJO, Wennmann M, Glemser PA, et al
    Same-day repeatability and Between-Sequence reproducibility of Mean ADC in PI-RADS lesions.
    Eur J Radiol. 2023;165:110898.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.